John Rondoni Sells 583 Shares of Inspire Medical Systems, Inc. (NYSE:INSP) Stock

Inspire Medical Systems, Inc. (NYSE:INSP) CTO John Rondoni sold 583 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

John Rondoni also recently made the following trade(s):

• On Tuesday, January 7th, John Rondoni sold 58 shares of Inspire Medical Systems stock. The stock was sold at an average price of $215.00, for a total value of $12,470.00.

Inspire Medical Systems Price Performance

Shares of INSP opened at $184.73 on Friday. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40. The stock has a market cap of $5.54 billion, a PE ratio of 172.65 and a beta of 1.32. The firm has a fifty day moving average price of $189.11 and a 200 day moving average price of $191.33.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 1.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSP. Vanguard Group Inc. grew its position in shares of Inspire Medical Systems by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company’s stock worth $606,259,000 after acquiring an additional 38,219 shares during the last quarter. Wasatch Advisors LP grew its position in Inspire Medical Systems by 1.6% during the 3rd quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company’s stock worth $279,318,000 after purchasing an additional 20,481 shares during the last quarter. State Street Corp grew its position in Inspire Medical Systems by 78.0% during the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock worth $221,557,000 after purchasing an additional 459,990 shares during the last quarter. Invesco Ltd. increased its stake in Inspire Medical Systems by 14.3% in the fourth quarter. Invesco Ltd. now owns 793,080 shares of the company’s stock valued at $147,021,000 after purchasing an additional 99,030 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Inspire Medical Systems by 5.8% in the third quarter. Janus Henderson Group PLC now owns 502,609 shares of the company’s stock valued at $106,075,000 after buying an additional 27,374 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on INSP. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a research note on Tuesday. KeyCorp reaffirmed an “overweight” rating and issued a $234.00 target price (down previously from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Robert W. Baird lowered their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a report on Tuesday, January 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research note on Tuesday. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $228.82.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.